Correction to: Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies

Simona Fecarotta,Arunabha Ghosh,Sachin Marulkar,Simon A. Jones,Anais Brassier,Florian Abel,Suresh Vijay

doi:10.1186/s13023-021-01753-0

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Highlights

Following the publication of the original article [1], we were informed that the Plain Language Summary had inadvertently been omitted during typesetting
If left untreated, Lysosomal acid lipase deficiency (LAL-D) in infants leads to death, usually by 6 months of age
*Correspondence: suresh.vijay1@nhs.net 1 Birmingham Children’s Hospital NHS Foundation Trust, Steelhouse Lane, Birmingham B4 6NH, UK Full list of author information is available at the end of the article

Summary

Introduction

Correction to: Long‐term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open‐label studies Suresh Vijay1*, Anais Brassier2, Arunabha Ghosh3, Simona Fecarotta4, Florian Abel5, Sachin Marulkar5 and Simon A. Following the publication of the original article [1], we were informed that the Plain Language Summary had inadvertently been omitted during typesetting.

Results

Conclusion